Jenrin Discovery is developing potential therapeutics for chronic diseases includingNAFLD/NASH, diabetes and obesity.

Jenrin Discovery is developing potential therapeutics for chronic diseases including NAFLD/NASH, diabetes and obesity. Its focus is proprietary small molecule drugs designed to selectively target peripheral receptors. It has completed pre-clinical testing and GLP safety studies for its lead compound, JD5037, and is planning on filing the IND application by the second quarter in 2017. This agent provides a mechanism of action to treat NASH and related pathologies.
Industry: Health
Status: Active

Contact Information

r.chorvat@jenrindiscovery.com

Robert J Chorvat

CSO and Co-Founder

Ross Barrett

Founder